Skip to content
10-Q

Quarterly Report

FENNEC PHARMACEUTICALS INC. FENC

0001104659-26-061213

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 34.74M sh
Shares Diluted Q1 2026 · Mar 31, 2026 35.55M sh
Shares Diluted Q1 2026 · Mar 31, 2025 27.58M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 $2.38M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$4.32M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $40.18M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $36.79M
Stockholders Equity Q1 2026 · Mar 31, 2026 $37.68M
Stockholders Equity Q1 2026 · Dec 31, 2025 $35.47M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$5.88M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$5.87M
Current Liabilities Q1 2026 · Mar 31, 2026 $9.59M
Current Liabilities Q1 2026 · Dec 31, 2025 $10.52M
Total Liabilities Q1 2026 · Mar 31, 2026 $34.15M
Total Liabilities Q1 2026 · Dec 31, 2025 $35.08M
Current Assets Q1 2026 · Mar 31, 2026 $66.88M
Current Assets Q1 2026 · Dec 31, 2025 $67.04M
Total Assets Q1 2026 · Mar 31, 2026 $71.82M
Total Assets Q1 2026 · Dec 31, 2025 $70.55M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.01
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.04
Eps Basic Q1 2026 · Mar 31, 2026 $0.01
Eps Basic Q1 2026 · Mar 31, 2025 −$0.04
Sga Expense Q1 2026 · Mar 31, 2026 $3.19M
Sga Expense restated Q1 2026 · Mar 31, 2025 $5.87M
Rd Expense Q1 2026 · Mar 31, 2026 $49K
Rd Expense Q1 2026 · Mar 31, 2025 $94K
Net Income Q1 2026 · Mar 31, 2026 $201K
Net Income Q1 2026 · Mar 31, 2025 −$1.17M
Operating Income Q1 2026 · Mar 31, 2026 −$119K
Operating Income Q1 2026 · Mar 31, 2025 −$808K
Revenue Q1 2026 · Mar 31, 2026 $15.11M
Revenue Q1 2026 · Mar 31, 2025 $8.75M